Mymd Pharmaceuticals (NASDAQ:QCLS) Releases Quarterly Earnings Results

Mymd Pharmaceuticals (NASDAQ:QCLS) released its quarterly earnings results on Friday. The company reported ($0.19) earnings per share (EPS) for the quarter, Zacks reports.

Mymd Pharmaceuticals Stock Performance

NASDAQ:QCLS opened at $4.33 on Friday. The stock has a market capitalization of $18.06 million, a P/E ratio of -0.04 and a beta of 2.11. Mymd Pharmaceuticals has a 52-week low of $2.50 and a 52-week high of $33.56.

Wall Street Analyst Weigh In

Separately, Weiss Ratings began coverage on Mymd Pharmaceuticals in a research note on Wednesday. They issued a “sell (e+)” rating on the stock. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.